Please login to the form below

Not currently logged in
Email:
Password:

Kite bags $90m upfront in two Asian deals for lead CAR-T drug

Partners with Daiichi Sankyo and Fosun Pharma to focus in on non-Hodgkin lymphoma

Kite PharmaKite Pharma has forged cancer immunotherapy alliances in Japan and China as it expands its business into Asian markets.

In China, Kite has formed a joint venture with Chinese drugmaker Fosun Pharma to develop lead chimeric antigen receptor T cell (CAR-T) therapy axicabtagene ciloleucel (also known as KTE-C19), which has been submitted for approval in the US via a rolling marketing application.

That deal nets the US biotech $40m in upfront payments, plus $20m of funding to support clinical development and manufacturing and $35m in regulatory and commercial milestones, and Kite will own 50% of the new company.

The Shanghai-based JV has also taken an option to develop two other candidates - KITE-718, a MAGE A3/A6-directed therapy for solid tumours, and KITE-439, which targets human papillomavirus type 16 E7 oncoprotein. Opt-in and milestone payments for these two candidates could reach $140m.

Kite's Japanese partnership is with Daiichi Sankyo and will see Kite receive $50m upfront and $200m in development and commercial milestone payments in return for rights to axicabtagene ciloleucel. Daiichi Sankyo is also taking an option to license KITE-718 plus "certain other product candidates that proceed to a US investigational new drug application filing over the next three years".

Kite has submitted axicabtagene ciloleucel as a treatment for patients with refractory aggressive non-Hodgkin lymphoma (NHL) in the US, and is vying with Novartis to be the first company to win marketing approval anywhere in the world for a CAR-T therapy.

The therapy involves harvesting patient's T cells and engineering them to express a chimeric antigen receptor (CAR) that targets CD19, an antigen expressed on the cell surface of B-cell lymphomas and leukaemias, which redirects the T cells to kill cancer cells.

The two new deals could unlock a sizeable new patient population for axicabtagene ciloleucel - there are approximately 73,000 newly-diagnosed cases of NHL in China each year, while Japan has around 9,300 new cases.

Article by
Phil Taylor

11th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
nitrogen

nitrogen is a strategic brand experience agency which blends science and imagination; delivering multi-channel communications that are both compelling and...

Latest intelligence

Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...
eyeforpharma Barcelona 2017 highlights: Industry at the brink of transformation
Hear what Anthill's delegates reported back from the biggest eyeforpharma Barcelona yet....

Infographics